The value of survival gains from therapeutic innovations for US patients with relapsed/refractory multiple myeloma.

ABSTRACT:

Aims

This study quantifies the value of survival gains attributable to novel treatments approved since 2003 for United States (US) patients with relapsed/refractory multiple myeloma (RRMM).

Methods

We estimated the increase in survival attributable to lenalidomide and bortezomib for multiple myeloma (MM) patients in the 1983-2013 Surveillance, Epidemiology, and End Results (SEER) registry. To estimate the survival benefit of treatments approved since 2015 (carfilzomib, elotuzomab, daratumumab, used in combination with lenalidomide and dexamethasone) we used clinical trial data to calibrate survival estimated using the SEER data. We then conducted an economic valuation of the estimated shift in survival curves for all therapies. Finally, we estimated the share of the value ac

SUBMITTER: MacEwan JP 

PROVIDER: S-EPMC8255558 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature